Condition: Chronic Hepaititis B · Sponsor: nChroma Bio
This is an open-label study with single- and multiple-ascending dose arms followed by a dose expansion arm. The primary objective of the study is to determine the safety and tolerability of CRMA-1001 in adult participants with Chronic Hepatitis B. In addition, the pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of CRMA-1001 will be evaluated. CRMA-1001 is an epigenetic gene therapy delivered via intravenous (IV) infusion. Up to four dose levels will be tested. Participants will receive a single or multiple doses of CRMA-1001 and will remain on antiviral therapy during the dosing process.
This description comes directly from the study's public registry record.
nChroma Bio · (617) 915 6203 · CRMA-1001-101-Study@nchromabio.com
Always discuss trial participation with your own doctor first.
| Hospices Civils De Leon | Lyon, France | Recruiting |
| Queen Mary Hospital, The University of Hong Kong | Hong Kong, Hong Kong | Recruiting |
| New Zealand Clinical Research | Auckland, New Zealand | Recruiting |
| King's College Hospital | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07200193